Clik here to view.
Transgenomic and University of Melbourne Collaborate to Further Validate...
OMAHA, Neb. Transgenomic, Inc. (NASDAQ:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and...
View ArticleClik here to view.
ImpediMed Announced Medicare Payment for New L-Dex® Category I Code
BRISBANE, Australia & SAN DIEGO ImpediMed (ASX:IPD) is pleased to announce today the Centers for Medicare and Medicaid Services (CMS) has published the valuation for CPT® Category I Code 93702...
View ArticleClik here to view.
Takeda Announces Abstracts for ADCETRIS® (brentuximab vedotin) in Hodgkin...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502) today announced that abstracts of interest from studies on VELCADE® (bortezomib), ADCETRIS® (brentuximab vedotin)...
View ArticleClik here to view.
武田宣布，ADCETRIS® (brentuximab...
马萨诸塞州坎布里奇和日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE:4502)今天宣布，该公司关注的VELCADE® （硼替佐米）、ADCETRIS® (brentuximab vedotin)和研究中的口服蛋白酶体抑制剂ixazomib...
View ArticleClik here to view.
GE Healthcare and Takeda Join Forces to Develop Therapeutic Drugs to Target...
CHALFONT ST. GILES, England & OSAKA, Japan GE Healthcare and Takeda Pharmaceutical Company announced that they have entered into an alliance agreement for research and development in the field...
View ArticleClik here to view.
エリテックが大腸菌由来およびエルウィニア菌由来のアスパラギナーゼにアレルギーを持つALL患者でのGRASPA®使用についての良好な初期結果をASHにて発表へ
仏リヨン （ビジネスワイヤ） — 急性白血病および医療ニーズが満たされていないその他の腫瘍適応症を対象に革新的な「腫瘍飢餓化」治療薬の開発に当たっているフランスのバイオ製薬企業エリテック（Paris:ERYP）（Euronext Paris: FR0011471135 –...
View ArticleClik here to view.
Immune Checkpoint Inhibitors Market to Witness 24.1% Annualised Growth,...
LONDON Roots Analysis has announced the addition of “Immune Checkpoint Inhibitors Market, 2014-2024” report to their offering. The study offers a comprehensive view of the emerging market of CTLA-4,...
View ArticleClik here to view.
Clik here to view.
全球调研发现，欧美许多人基本上不了解胰腺癌这一主要的致死性癌症
新泽西州萨米特 (美国商业资讯) –当人们听到“癌症”这个词时，首先想到乳腺癌和肺癌，这可能不足为奇，而近期一项6个国家参与的癌症知晓度调研显示，60%的受访者几乎不知道胰腺癌这一主要的癌症杀手。胰腺癌是美国排行第四的癌症相关死因，预计到2020年，将成为美国第二大癌症死因。在欧美，胰腺癌的5年总生存率不到7%；这项生存率多年来一直很低，在美国和欧洲多数国家常见癌症生存率中位列最低之一。...
View ArticleClik here to view.
BeiGene Completes 450 Million RMB (75 Million USD) Financing
BEIJING BeiGene, LTD., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the successful completion of a financing of over 450 million...
View ArticleClik here to view.
CORRECTING and REPLACING BeiGene Completes 450 Million RMB (75 Million USD)...
BEIJING In the release dated November 14, 2014, references to “CITIC Capital Partners” should be “CITIC PE”. The boilerplate for CITIC Capital Partners should be replaced with the CITIC PE...
View ArticleClik here to view.
TechNavio Says Increased Outsourcing Activities Will Positively Affect Profit...
LONDON TechNavio, a tech-focused research firm has published a new report on the Global Oncology Biosimilars Market, which is expected to grow at a CAGR of 29.87 percent from 2014-2018. A good...
View ArticleClik here to view.
PharmaEngine Announces the Receipt of US FDA Fast Track Designation for...
TAIPEI, Taiwan PharmaEngine, Inc. (TWO: 4162) and its partner Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) announced today that MM-398 (nanoliposomal irinotecan injection, also known as PEP02) has...
View ArticleClik here to view.
Cell Signaling Technology Wins “Best Antibodies” and “Most Useful Website” at...
WASHINGTON Cell Signaling Technology, a leading provider of antibodies, kits and services, announced today that it has won two Life Science Industry Awards® for “Best Antibodies” and “Most Useful...
View ArticleClik here to view.
CSTが「最も優れた抗体」および「最も有益なウェブサイト」の部門でライフサイエンス・インダストリー・アワードを受賞
ワシントン （ビジネスワイヤ）– 抗体、キット、サービスを提供する一流企業のセル・シグナリング・テクノロジー（CST）は本日、「最も優れた抗体」（Best Antibodies）および「最も有益なウェブサイト」（Most Useful Website）の2部門でライフサイエンス・インダストリー・アワード（Life Science Industry...
View ArticleClik here to view.
HanAll Biopharma Co., Ltd. and Open Monoclonal Technology Announce Collaboration
SEOUL, South Korea & PALO ALTO, Calif. HanAll BioPharma Co., Ltd. (HanAll), a public Korean biopharmaceutical company and leader in development of novel biologics and new chemical entities in...
View ArticleClik here to view.
CANbridge Life Sciences Raises $10 Million in Series A Round Led by Qiming...
BEIJING CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, announced that it has raised $10 million in a Series A round from...
View ArticleClik here to view.
Elekta Ltd and Medical Intelligence Medizintechnik GmbH defend claims by...
CRAWLEY, United Kingdom Regulatory News: humediQ GmbH has initiated legal proceedings against two companies in the Elekta (STO:EKTAB) (EKTA-B.ST) group. The dispute relates to an agreement from...
View ArticleClik here to view.
テラヴェクティスが自社レンチウイルスベクター技術の知的財産権をさらに強化
パリ （ビジネスワイヤ） — 完全統合型の創薬・臨床開発バイオテクノロジーを手掛ける企業として治療用ワクチンと免疫療法の開発に傾注するテラヴェクティスは、最初の申請（ウェブサイト）からわずか2年後に欧州特許「Lentiviral Vectors Containing an MHC Class I...
View ArticleClik here to view.
Takeda Announces Formalization of Takeda Oncology to Enhance Discovery,...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502) today announced its global oncology business unit, headquartered in Cambridge, MA, will be called Takeda...
View Article